Business
On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” areas of focus for the pharma.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Arie Belldegrun, the co-founder and executive chairman of the board of Allogene, disclosed this weekend that he has been diagnosed with COVID-19. The pharma entrepreneur is in self-quarantine and is doing well.
Under the terms of the agreement, AbCellera and Lilly have committed to equally share initial development costs towards a product, after which Lilly will be responsible for all further development, manufacturing and distribution.
Companies strengthen their leadership teams and executive boards with this week’s Movers & Shakers.
The new company is focused on tapping into the powers of the immune system to address numerous diseases.
No financial terms were disclosed.
Pharming Group N.V. announced that its Chief Financial Officer, Robin Wright, has decided not to put himself up for re-election as a member of the Board of Management and thus as Chief Financial Officer at the upcoming General Meeting of Shareholders on 20 May 2020 and that, as result of this decision, his term with the Company will end as at that date..
WindMIL Therapeutics and Cognate BioServices, Inc. announced they have entered an agreement to expand WindMIL’s clinical manufacturing capacity.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2020. We want to know how the coronavirus outbreak may be impacting your work and your workplace.
Cell Medica has rebranded itself as Kuur Therapeutics as it dives into the development of anti-cancer therapies using its innovative chimeric antigen receptor natural killer T cell therapy platform.
Numerous organizations are cancelling or postponing activities that involve large groups of people.